Please verify

Blaze Media
Watch LIVE

Pfizer and BioNTech combination COVID-19 and flu vaccine could be on the horizon

JOEL SAGET/AFP via Getty Images

Pfizer and BioNTech have announced the launch of a phase 1 trial for a dual-purpose mRNA-based vaccine to tackle both influenza and COVID-19.

"The vaccine candidate combines Pfizer’s quadrivalent modRNA-based influenza vaccine candidate, qIRV (22/23), which is currently in Phase 3 clinical development, and Pfizer and BioNTech’s authorized Omicron-adapted bivalent COVID-19 BNT162b2 (Original/Omicron BA.4/BA.5) vaccine, each of which is based on BioNTech’s proprietary mRNA platform technology," according to a press release.

Read MoreShow less
Most recent
All Articles